SALARIUS PHARMACEUTICALS INC (SLRX) Stock Price, Forecast & Analysis
NASDAQ:SLRX • US79400X5032
SLRX Key Statistics, Chart & Performance
The current stock price of SLRX is 0.84 USD. In the past month the price increased by 1.2%. In the past year, price decreased by -96.42%.
SLRX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SLRX. When comparing the yearly performance of all stocks, SLRX is a bad performer in the overall market: 99.58% of all stocks are doing better.
SLRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SLRX. The financial health of SLRX is average, but there are quite some concerns on its profitability.
SLRX Financial Highlights
Over the last trailing twelve months SLRX reported a non-GAAP Earnings per Share(EPS) of -39.18. The EPS increased by 68.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.08% | ||
| ROE | -117.81% | ||
| Debt/Equity | 0 |
SLRX Forecast & Estimates
SLRX Ownership
SLRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 402.079B | ||
| AMGN | AMGEN INC | 16.25 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.985B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.174B | ||
| BIIB | BIOGEN INC | 12.85 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SLRX
Company Profile
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. The company is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
Company Info
SALARIUS PHARMACEUTICALS INC
2450 Holcombe Blvd Ste J-608
Houston TEXAS 77021 US
CEO: David J. Arthur
Employees: 2
Phone: 13467720346
SALARIUS PHARMACEUTICALS INC / SLRX FAQ
Can you describe the business of SALARIUS PHARMACEUTICALS INC?
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. The company is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
What is the current price of SLRX stock?
The current stock price of SLRX is 0.84 USD. The price increased by 29.23% in the last trading session.
Does SLRX stock pay dividends?
SLRX does not pay a dividend.
What is the ChartMill rating of SALARIUS PHARMACEUTICALS INC stock?
SLRX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How many employees does SALARIUS PHARMACEUTICALS INC have?
SALARIUS PHARMACEUTICALS INC (SLRX) currently has 2 employees.
What is the market capitalization of SLRX stock?
SALARIUS PHARMACEUTICALS INC (SLRX) has a market capitalization of 4.92M USD. This makes SLRX a Nano Cap stock.